Publications by authors named "M Szarek"
Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS. This post hoc analysis of ODYSSEY OUTCOMES assessed the effect of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, on the incidence of chest pain not due to recurrent ACS.
Methods: Patients with recent ACS ( = 18,894) and elevated atherogenic lipoprotein levels despite optimized statin therapy were randomized to subcutaneous alirocumab or matching placebo every 2 weeks.
Importance: Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.
Objective: To evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on lipoprotein(a) serum concentration.
Design, Setting, And Participants: A multicenter trial in patients with stable ASCVD with serum lipoprotein(a) concentrations greater than or equal to 125 nmol/L at 26 sites in Europe and South Africa between January 3, 2023, and April 27, 2023, with last follow-up on July 1, 2024.
Article Synopsis
- SGLT2 inhibitors like sotagliflozin show promise in improving health status for heart failure patients, but effects of SGLT1/SGLT2 inhibition remain unclear.* -
- In the SOLOIST-WHF trial, patients taking sotagliflozin after a heart failure episode experienced a significant improvement in their Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) scores compared to those on placebo.* -
- Overall, sotagliflozin not only reduced hospitalizations and cardiovascular deaths but also led to improved symptoms and quality of life within four months, benefiting patients regardless of their left ventricular ejection fraction.*
Article Synopsis
- The study investigates the relationship between triglyceride levels and the cardiovascular benefits of alirocumab compared to placebo in patients with recent acute coronary syndrome (ACS) who are on statin therapy.
- Results showed that higher baseline triglyceride levels were linked to an increased risk of major adverse cardiovascular events (MACE), whereas alirocumab significantly lowered LDL cholesterol and reduced MACE risk.
- While alirocumab led to a notable decrease in triglycerides, the reduction did not correlate with a lower risk of MACE, suggesting baseline triglyceride levels are more important for cardiovascular risk than reductions achieved through treatment.